New fusion proteins study findings have been reported by A. Eguchi and colleagues
2009 JUL 13 - (NewsRx.com) -- According to recent research from the United States, "RNA interference (RNAi) induced by short interfering RNA (siRNA) allows for discovery research and large-scale screening(1-5); however, owing to their size and anionic charge, siRNAs do not readily enter cells(4,5). Current approaches do not deliver siRNAs into a high percentage of primary cells without cytotoxicity." "Here we report an efficient siRNA delivery approach that uses a peptide transduction domain-double-stranded RNA-binding domain (PTD-DRBD) fusion protein. DRBDs bind to siRNAs with high avidity, masking the siRNA's negative charge and allowing PTD-mediated cellular uptake. PTD-DRBD-delivered siRNA induced rapid RNAi in a large percentage of various primary and transformed cells, including T cells, human umbilical vein endothelial cells and human embryonic stem cells. We observed no cytotoxicity, minimal off-target transcriptional changes and no induction of innate immune responses," wrote A. Eguchi and colleagues. The researchers concluded: "Thus, PTD-DRBD-mediated siRNA delivery allows efficient gene silencing in difficult-to-transfect primary cell types." Eguchi and colleagues published their study in Nature Biotechnology (Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nature Biotechnology, 2009;27(6):567-U110). For additional information, contact S.F. Dowdy, UCSD, School Medical, Howard Hughes Med Institute, La Jolla, CA 92093, USA. Publisher contact information for the journal Nature Biotechnology is: Nature Publishing Group, 75 Varick St., 9TH Flr, New York, NY 10013-1917, USA. Keywords: United States, La Jolla, Biotechnology, Gene Therapy, Proteomics. Fusion Proteins. This article was prepared by Proteomics Weekly editors from staff and other reports. Copyright 2009, Proteomics Weekly via NewsRx.com.
|
